Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, comments on the final results of the BFORE trial, which produced data suggesting that bosutinib was more effective than imatinib in generating and maintaining a deep molecular response in patients across the Sokal score spectrum. The safety profile remained stable, with any intolerances largely limited to the first year of treatment.